Ocular allergy/inflammation:
Indications for: ALREX
Seasonal allergic conjunctivitis.
Clinical Trials:
In two double-masked, placebo-controlled six-week environmental studies of 268 patients with seasonal allergic conjunctivitis, Alrex, when dosed 4 times per day was superior to placebo in the treatment of the signs and symptoms of seasonal allergic conjunctivitis. Alrex reduced bulbar conjunctival injection and itching, beginning approximately 2 hours after instillation of the first dose and throughout the first 14 days of treatment.
Adult Dosage:
1 drop into affected eye(s) 4 times daily.
Children Dosage:
Not recommended.
ALREX Contraindications:
Ocular fungal, viral, or mycobacterial infections.
ALREX Warnings/Precautions:
Reevaluate if no improvement after 2 days. Prescribe initially and renew after 14 days only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Soft contact lenses (remove, may reinsert 10 minutes after instillation). Pregnancy (Cat.C). Nursing mothers.
ALREX Classification:
Steroid.
Adverse Reactions:
Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation.
Drug Elimination:
Fecal.
How Supplied:
Susp—5mL, 10mL
